4.62
+0.08(+1.76%)
Currency In USD
| Previous Close | 4.54 |
| Open | 4.5 |
| Day High | 4.65 |
| Day Low | 4.39 |
| 52-Week High | 7.3 |
| 52-Week Low | 2.37 |
| Volume | 1.6M |
| Average Volume | 887,668 |
| Market Cap | 590.72M |
| PE | -42 |
| EPS | -0.11 |
| Moving Average 50 Days | 3.94 |
| Moving Average 200 Days | 3.91 |
| Change | 0.08 |
If you invested $1000 in Cytek Biosciences, Inc. (CTKB) since IPO date, it would be worth $246.27 as of November 08, 2025 at a share price of $4.62. Whereas If you bought $1000 worth of Cytek Biosciences, Inc. (CTKB) shares 3 years ago, it would be worth $318.18 as of November 08, 2025 at a share price of $4.62.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year
GlobeNewswire Inc.
Nov 06, 2025 10:00 PM GMT
BioTech Breakthrough Awards The Cytek® Muse® Micro cell analyzer has been named Drug Discovery Solution of the Year in the 2025 BioTech Breakthrough Awards. FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CT
Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry
GlobeNewswire Inc.
Oct 29, 2025 9:00 PM GMT
Supports ISAC in Mission to Extend Flow Cytometry Reach Worldwide; Unveils Programs Offering Instrument Award and Research Grants Cytek research initiative Cytek is supporting ISAC in a shared mission to extend flow cytometry reach worldwide. In th
Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025
GlobeNewswire Inc.
Oct 22, 2025 8:05 PM GMT
FREMONT, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2025 after market close on Wednesday, November 5, 202